Deep search
Rewards
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Ocrevus Zunovo now approved in US to treat relapsing MS, PPMS
The FDA approved Ocrevus Zunovo, a subcutaneous formulation of Ocrevus, for adults with relapsing forms of MS and PPMS
FDA approves Roche’s Ocrevus Zunovo with Halozyme Enhanze delivery tech
Roche has secured approval from the US Food and Drug Administration (FDA) for Ocrevus Zunovo (ocrelizumab and hyaluronidase-ocsq) with biopharmaceutical company Halozyme Therapeutics's Enhanze drug delivery technology.
Back-To-Back FDA Approvals For Roche's Two Under-The-Skin Injections
The FDA has approved Roche's Ocrevus Zunovo for relapsing and primary progressive multiple sclerosis, offering the first twice-a-year subcutaneous injection option for both forms of the disease.
Roche's OCREVUS ZUNOVO Gets FDA Approval To Treat Relapsing And Progressive Multiple Sclerosis
Swiss drug major Roche (RHHBY) announced Monday that the United States Food and Drug Administration has approved OCREVUS ZUNOVO
pharmaphorum
2d
Sanofi's tolebrutinib cuts MS progression by 31% in trial
Data from the HERCULES trial presented at the ECTRIMS conference in Copenhagen, Denmark, today showed that tolebrutinib was ...
The American Journal of Managed Care
5d
Subcutaneous Ocrelizumab and Hyaluronidase Approved for RMS, PPMS
Ocrelizumab and hyaluronidase is now the first and only twice-yearly subcutaneous injection approved for relapsing multiple ...
Medscape
1d
McDonald Criteria Update Aims to Simplify, Speed MS Diagnosis
MS experts are recommending updates to the 2017 McDonald diagnostic criteria that aim to make diagnosis easier, faster and more accurate.
4d
Three Key Items to Evaluate When Choosing a 721 Exchange
A REIT's debt levels, interest rate issues and financial performance are important factors when deciding which DST with a 721 ...
Medpage Today on MSN
26d
How Progressive Multiple Sclerosis Differs From Relapsing-Remitting MS
PPMS
typically includes a steady loss of function from the onset of symptoms. The vast majority of people with MS receive ...
Medscape
7d
A Trial of Rituximab for Primary Progressive Multiple Sclerosis
Other MS patients, a minority, have a form of the disease that features gradually increasing progressive disability from onset—so-called primary progressive MS (
PPMS
). While effective disease ...
6d
China patent notification boosts PolTREG’s development of Treg cell therapy in multiple sclerosis
China’s National Intellectual Property Administration has issued notification to grant patent to PolTREG Chinese patent covers intrathecal ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback